Assignee
ORBSEN THERAPEUTICS LTD
IE·15 granted patents·6 pending applications·57 citations·filing 2013–2025
Top patents by PatentIndex Score
21 records- 0196US11434471B2Stromal stem cellsORBSEN THERAPEUTICS LTD·Filed 2021·Granted Sep 6, 2022·4 cites·13 claims
- 0296US10920197B2Stromal stem cellsORBSEN THERAPEUTICS LTD·Filed 2019·Granted Feb 16, 2021·9 cites·9 claims
- 0393US11142747B2Stromal stem cellsORBSEN THERAPEUTICS LTD·Filed 2018·Granted Oct 12, 2021·4 cites·19 claims
- 0493US10907131B2Stromal stem cellsORBSEN THERAPEUTICS LTD·Filed 2016·Granted Feb 2, 2021·5 cites·18 claims
- 0592US11026994B2Syndecan-2 compositions and methods of useORBSEN THERAPEUTICS LTD·Filed 2019·Granted Jun 8, 2021·11 cites·20 claims
- 0690US2024209319A1Stromal stem cellsORBSEN THERAPEUTICS LTD·Filed 2024·Application pending·0 cites
- 0789US11884936B2Stromal stem cellsORBSEN THERAPEUTICS LTD·Filed 2023·Granted Jan 30, 2024·0 cites·11 claims
- 0888US11952590B2Stromal stem cellsORBSEN THERAPEUTICS LTD·Filed 2023·Granted Apr 9, 2024·0 cites·11 claims
- 0988US11952589B2Stromal stem cellsORBSEN THERAPEUTICS LTD·Filed 2023·Granted Apr 9, 2024·0 cites·19 claims
- 1087US10124038B2Modulators of syndecan-2 and uses thereofORBSEN THERAPEUTICS LTD·Filed 2016·Granted Nov 13, 2018·10 cites·12 claims
- 1186US11230700B2Stromal stem cellsORBSEN THERAPEUTICS LTD·Filed 2013·Granted Jan 25, 2022·3 cites·5 claims
- 1286US10251934B2Syndecan-2 compositions and methods of useORBSEN THERAPEUTICS LTD·Filed 2014·Granted Apr 9, 2019·8 cites·20 claims
- 1382US11268067B2Methods of isolation and use of CD39 stromal stem cellsORBSEN THERAPEUTICS LTD·Filed 2018·Granted Mar 8, 2022·3 cites·9 claims
- 1481US11926848B2Stromal stem cellsORBSEN THERAPEUTICS LTD·Filed 2021·Granted Mar 12, 2024·0 cites·11 claims
- 1574US2024245606A1Sdc-2 exosome compositions and methods of isolation and useORBSEN THERAPEUTICS LTD·Filed 2024·Application pending·0 cites
- 1670US2025268944A1Stromal stem cell therapeutics and methods of useORBSEN THERAPEUTICS LTD·Filed 2025·Application pending·0 cites
- 1764US11903997B2Modulators of syndecan-2 and uses thereofORBSEN THERAPEUTICS LTD·Filed 2018·Granted Feb 20, 2024·0 cites·9 claims
- 1862US11918687B2SDC-2 exosome compositions and methods of isolation and useORBSEN THERAPEUTICS LTD·Filed 2017·Granted Mar 5, 2024·0 cites·7 claims
- 1960US2022228122A1Methods of isolation and use of cd39 stromal stem cellsORBSEN THERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 2052US2022288129A1Compositions for monocyte and macrophage polarization and methods of useORBSEN THERAPEUTICS LTD·Filed 2020·Application pending·0 cites
- 2146US2021154235A1Stromal stem cell therapeutics and methods of useORBSEN THERAPEUTICS LTD·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when ORBSEN THERAPEUTICS LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →